The effect of Carboplatin and Bevacizumab on progression free survival in recurrent Glioblastoma Multiforme: A randomised phase II study.
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Etoposide; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CABARET
- 05 Jul 2017 Results published in the Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to results presented at ASCO 2015.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History